Lymph Node Thyroglobulin Measurement in Diagnosis of Neck Metastases of Differentiated Thyroid Carcinoma

Table 1

Patients characteristics and cytological, pathological, and biochemical data.

Patients	Histology	pTNM	Duration (months)	Tg (ng/mL)	TgAb (IU/mL)	Lesions	Sites	FNA		Final diagnosis
								Cytology	Tg (ng/mL)
1	PTC	pT1N1Mx	6	1.0	<60	1	R II	ND	<0.2	B
2	PTC	pT1NxMx	15	4.6	<60	1	L III	Negative	435.2	M
3	PTC	pT1NxMx	18	1.7	<60	1	R IV	CTM	85.3	M
4	PTC	pT1NxMx	30	0.4	<60	1	R III	ND	<0.2	B
5	PTC	pT1N0Mx	6	3.1	<60	1	L II	ND	97.2	M
6	PTC	pT2N0Mx	19	9.1	<60	2	R IV, VI	CTM	118.5	M
7	PTC	pT2NxMx	47	<0.2	334	1	L IV	CTM	879.4	M
8	PTC	pT2N1Mx	6	0.9	78	1	VI	Negative	1.1	B
9	PTC	pT1N1Mx	9	9.8	<60	1	L II	ND	1348.6	M
10	PTC	pT2N0Mx	14	1.5	<60	1	L III	CTM	358.5	M
11	PTC	pT1NxMx	8	12.6	<60	3	R II	CTM	2387.4	M
12	PTC	pT2NxMx	16	9.7	<60	1	R III	CTM	875.9	M
13	PTC	pT1NxMx	9	6.3	<60	1	R II	CTM	958.6	M
14	PTC	pT1N0Mx	11	1.0	<60	1	L III	Negative	48.7	M
15	PTC	pT2N1Mx	39	9.5	<60	1	L IV	CTM	>3000	M
16	PTC	pT1NxMx	12	0.8	<60	1	L III	CTM	107.5	M
17	PTC	pT2NxMx	19	2.7	<60	3	R III-IV	ND, CTM	541.6	RIII B, IV M
18	PTC	pT4N1Mx	6	1.6	<60	1	L III	CTM	31.8	M
19	PTC	pT1N1Mx	15	0.5	289	1	R IV	ND	<0.2	B
20	PTC	pT2N1Mx	3	2.3	<60	1	L III	ND	540.7	M
21	PTC	pT1NxMx	34	4.1	<60	1	L III	CTM	650.6	M
22	PTC	pT2N1Mx	8	<0.2	98	1	L II	ND	5.8	M
23	PTC	pT1NxMx	9	0.8	<60	2	R II, R III	CTM	87.5	M
24	PTC	pT4N0Mx	10	1.4	755	1	R II	CTM	196.4	M
25	PTC	pT2NxMx	21	11	<60	1	R III	ND	585.3	M
26	PTC	pT1NxMx	9	<0.2	<60	1	R III	Negative	<0.2	B
27	PTC	pT4N1M	12	1.1	160	1	L III	Negative	0.3	B
28	PTC	pT1N0Mx	23	5.3	<60	1	R III	CTM	784.2	M
29	PTC	pT2N1Mx	5	<0.2	>1000	1	R III	ND	<0.2	B
30	PTC	pT2N0Mx	22	4.9	<60	1	R III	CTM	641.5	M
31	PTC	pT1NxMx	36	0.3	367	1	R IV	Negative	<0.2	B
32	PTC	pT1NxMx	15	7.1	<60	1	R III	ND	665.4	M
33	PTC	pT2N0Mx	41	<0.2	<60	1	L II	Negative	<0.2	B
34	PTC	pT1NxMx	24	2.6	<60	1	R III	CTM	570.6	M
35	PTC	pT4N0Mx	31	1.4	>1000	3	L IV, VI	CTM	96.7	M
36	PTC	pT4N1M	12	27.1	<60	1	R II	CTM	2987.3	M
37	PTC	pT1N1Mx	54	6.8	<60	1	L III	CTM	875.6	M
38	PTC	pT2NxMx	12	<0.2	149	1	R IV	Negative	<0.2	B
39	PTC	pT2N0Mx	9	0.9	<60	1	R II	Negative	<0.2	B
40	PTC	pT1N0Mx	34	2.4	89	1	L III	ND	347.4	M
41	PTC	pT2NxMx	14	5.1	<60	1	L IV	ND	1655.7	M
42	PTC	pT4N1M	8	7.7	<60	1	L III	Negative	2076.5	M
43	PTC	pT1NxMx	61	1.1	<60	1	VI	Negative	<0.2	B
44	PTC	pT2N0Mx	22	1.0	<60	1	L II	CTM	90.6	M
45	PTC	pT2N1Mx	12	6.4	<60	2	R III-IV	CTM, ND	458.6	RIII M, IV B
46	PTC	pT1NxMx	45	0.6	<60	1	R IV	Negative	<0.2	B
47	PTC	pT4N0Mx	36	4.3	<60	1	R III	CTM	766.4	M
48	PTC	pT2NxMx	11	1.9	<60	1	L II	ND	306.5	M
49	PTC	pT3NxMx	18	7.0	<60	1	R III	CTM	955.6	M
50	PTC	pT2NxMx	10	1.2	<60	1	L III	Negative	<0.2	B
51	PTC	pT1N1Mx	12	3.9	<60	1	R III	CTM	564.7	M
52	PTC	pT3N0Mx	25	6.4	190	1	R III	ND	1078.6	M
53	PTC	pT2N1Mx	16	9.5	<60	1	L IV	CTM	759.4	M
54	PTC	pT1NxMx	9	0.6	<60	1	R III	Negative	<0.2	B
55	PTC	pT3N1Mx	60	<0.2	107	2	L II-III	CTM	137.5	M
56	PTC	pT1N0Mx	11	5.3	<60	1	R II	CTM	654.8	M
57	PTC	pT2N1Mx	18	1.1	860	1	L III	ND	<0.2	B
58	PTC	pT1NxMx	9	0.9	<60	1	R IV	Negative	<0.2	B
59	PTC	pT2NxMx	28	1.1	<60	1	R III	ND	99.6	M
60	PTC-TCV	pT3NxMx	13	4.6	<60	1	L II	CTM	436.8	M
61	PTC	pT1NxMx	2	2.7	<60	1	R II	CTM	194.5	M
62	PTC	pT3NxMx	7	21.9	<60	3	R III, L II	Neg., CTM	>3000	RIII B, LII M
63	PTC	pT1NxMx	18	1.1	<60	1	R III	CTM	27.4	M
64	PTC	pT3NxMx	10	3.5	<60	1	VI	CTM	147.4	M
65	PTC	pT2N0Mx	29	<0.2	>1000	1	R IV	Negative	<0.2	B
66	PTC	pT3N1Mx	6	5.6	<60	1	L III	CTM	<0.2	M
67	PTC	pT1N1Mx	11	2.1	<60	1	R III	ND	<0.2	M
68	PTC	pT3N0Mx	18	0.7	<60	1	R III	ND	<0.2	B
69	PTC	pT2N0Mx	23	1.7	<60	1	L IV	CTM	75.6	M
70	PTC	pT1NxMx	9	3.5	<60	1	L II	ND	72.6	M
71	PTC	pT3N0Mx	18	7.1	<60	2	R IV, VI	CTM	386.2	RIV B, VI M
72	PTC	pT1NxMx	7	1.8		1	L II	Negative	<0.2	B
73	PTC	pT2NxMx	11	3.6	<60	1	R III	ND	245.7	M
74	PTC	pT2NxMx	29	2.2	<60	2	L III-IV	CTM	67.4	IV M, III B
75	PTC	pT2N1Mx	14	5.7	<60	1	L II	CTM	198.7	M
76	PTC	pT1N0Mx	8	1.5	<60	1	R IV	CTM	26.1	M
77	PTC	pT2NxMx	10	2.1	<60	1	VI	CTM	59.7	M
78	PTC	pT1NxMx	18	0.7	<60	1	R IV	Negative	<0.2	B
79	PTC	pT3N1Mx	34	12.3	<60	1	R III	ND	678.4	M
80	PTC	pT1N1Mx	16	1.8	<60	1	L II	Negative	<0.2	B
81	PTC	pT2N0Mx	52	0.9	<60	1	R III	Negative	<0.2	B
82	PTC	pT2N1Mx	25	9.4	<60	1	L III	ND	563.6	M
83	PTC	pT1NxMx	9	4.1	<60	1	VI	CTM	64.7	M
84	PTC	pT2N1Mx	18	3.1	<60	1	R IV	CTM	116.4	M
85	PTC-TCV	pT2NxMx	20	15.5	<60	3	R IV-L III	CTM	432.9	M
86	PTC	pT3N0Mx	8	<0.2	56	1	VI	ND	<0.2	B
87	PTC	pT1N0Mx	31	2.9	<60	1	R IV	CTM	39.3	M
88	PTC	pT2NxMx	11	1.7	<60	1	R III	Negative	<0.2	B
89	PTC	pT2NxMx	54	6.5	<60	1	L IV	ND	467.7	M
90	PTC	pT1N1Mx	28	0.3	651	1	R II	Negative	<0.2	B
91	PTC	pT2NxMx	12	2.1	<60	1	L III	CTM	88.6	M
92	PTC	pT3N0Mx	17	9.4	<60	2	R IV, VI	CTM	156.2	IV M, VI B
93	PTC	pT1NxMx	22	1.0	<60	1	L IV	Negative	<0.2	B
94	PTC	pT2N1Mx	9	4.3	<60	1	VI	Negative	53.8	M
95	PTC	pT2N0Mx	26	<0.2	<60	1	R IV	Negative	<0.2	B
96	PTC	pT1N0Mx	12	0.9	<60	1	R III	ND	2.7	M
97	PTC	pT2NxMx	17	8.1	<60	1	L II	ND	356.4	M
98	PTC	pT2NxMx	9	0.9	<60	1	R III	CTM	19.6	M
99	PTC	pT3N1Mx	12	1.1	<60	1	L III	ND	0.6	B
100	FTC	pT1N1Mx	45	4.9	<60	1	R III	CTM	117.5	M
101	FTC	pT3N0Mx	36	1.4	<60	1	R III	Negative	<0.2	B
102	FTC	pT2N1Mx	11	<0.2	>1000	2	R III-IV	Negative	<0.2	B
103	FTC (HC)	pT1NxMx	72	10.4	<60	1	R IV	ND	278.9	M
104	FTC	pT2N1Mx	11	0.7	<60	1	R III	Negative	<0.2	B
105	FTC	pT1N0Mx	18	2.1	<60	1	R IV	CTM	74.4	M
106	FTC (HC)	pT1N0Mx	6	1.9	<60	1	L III	Negative	0.8	B
107	FTC	pT2N1Mx	25	7.8	<60	1	R II	ND	116.4	M
108	FTC	pT1NxMx	19	4.6	<60	2	L II-III	CTM	89.5	M

FNA, fine-needle aspiration; PTC, papillary thyroid carcinoma; FTC, follicular thyroid carcinoma; TCV, tall-cell variant; HC Hürtle cell; R, right, L, left; duration, time from thyroid ablation to FNA; II-III-IV, upper, middle, lower neck lateral compartment, IV, central neck compartment.